See allLatest Trade Alerts

Brokerage Partners

9 High-Yield Stocks to Consider in Lieu of Bonds

Written by: Frank Byrt 06/01/12 - 1:18 PM EDT
Tickers in this article: RCI SCCO PAYX LMT AZN TGT COP LLY MO

8. Paychex(PAYX)

Company profile: Paychex, with a market value of $11 billion, provides payroll accounting services to small and medium-sized businesses throughout the U.S.

Dividend Yield: 4.22%

More Headlines

Investor takeaway: Its shares are up 2% this year and have a 15-year, average annual return of 9%. Analysts give its shares three "buy" ratings, four "buy/holds," 16 "holds," one "weak hold," and two "sells," according to a survey of analysts by S&P. Analysts expect it will earn $1.52 per share this year and $1.64 next year, or 8% growth.

7. Riocan Real Estate Investment(RIOCF)

Company profile: Riocan, with a market value of $7 billion, is Canada's largest real estate investment trust exclusively focused on retail real estate. It owns and manages a large portfolio of shopping centers.

Dividend Yield: 4.46%

Investor takeaway: Its shares are up 0.3% this year and have a one-year annual return of 3.7%. Morningstar found three "buy" ratings and two "holds." BlackRock Asset Management Canada Ltd. owns 4.5% of its shares.

6. Lockheed Martin(LMT)

Company profile: Lockheed Martin, with a market value of $27 billion, is the largest defense contractor in the world and is the undisputed leader in next-generation fighter aircraft development.

Dividend Yield: 4.53%

Investor takeaway: Its shares are up 4.8% this year and have a 15-year, average annual return of 5.4%. Analysts give its shares two "buy" ratings, one "buy/hold," 16 "holds," two "weak holds," and two "sells," according to a survey of analysts by S&P. Analysts expect it will earn $7.88 per share this year and that that will grow by 7% to $8.42 per share next year.

5. Eli Lilly(LLY)

Company profile: Eli Lilly, with a market value of $48 billion, is one of the world's largest pharmaceutical companies, with a focus on neuroscience, endocrinology, oncology, and cardiovascular therapeutic areas. The company faces the challenge of a number of its patented drugs going to generic status over the next few years. However, it has many new drugs in its pipeline.

Dividend Yield: 4.78%